University College Hospital start EPI-589 Parkinson’s study

Medical background with many different symbols and icons

A new study, part of The Cure Parkinson’s Trust’s Linked Clinical Trials Programme, is starting at University College London Hospital (UCLH). The study is researching a new possible treatment, EPI-589, to explore whether it is well tolerated and could improve the biochemical profile in Parkinson’s patients.

The study will involve three months of drug treatment with clinical measures, blood tests and spinal fluid tests and it is hoped that this will be the first step in the development of a new Parkinson’s treatment.

The study is looking to recruit 20 patients with newly diagnosed, untreated Parkinson’s or a known genetic form of Parkinson’s (e.g. a parkin, PINK1 or LRRK2 gene change) that will most likely have been identified by an NHS gene test.

The treatment is being developed by Edison Pharmaceuticals and was initially aimed at children with mitochondrial disease (problems with energy production within cells) and research suggests that similar mechanisms may occur in some patients with Parkinson’s.

The study is being led by Professor Huw Morris and Dr Vincenzo Libri at the Leonard Wolfson Experimental Neurology Centre at UCLH in London.

If you are interested in participating please contact the study team on email LWENC-CRF@ucl.ac.uk or telephone 020 3448 4531. Further information can be found on the Clinical Trials website.

More information on genetic testing can be found on the Parkinson’s UK website

RELATED ITEMS

  • At our patient advocate Rallying to the Challenge Meeting in 2014 it was unanimously agreed in the value of developing a clinical trials charter to significantly improve communication between those taking part in trials and those running clinical trials. The Charter was developed by people living with Parkinson's and clinicians…
  • World Parkinson Congress 2016 World Parkinson Congress (WPC), the only Parkinson’s conference to draw together people with Parkinson’s, researchers and clinical experts took place in Portland, Oregon, USA from 20th to 23rd September 2016. We have just got back from a very busy and interesting trip! Tom Isaac honoured with Distinguished…
  • Dr David Devos is leading Europe-wide consortia of neurologists and Parkinson’s specialists to secure funding from the EU’s Horizon 2020 programme to run a clinical trial through 28 centres across Europe to understand the efficacy of Deferiprone, an iron-chelator in the treatment of people with Parkinson’s. 'The Cure Parkinson’s Trust…
  • The research folks are gradually narrowing in on the cause of Parkinson’s — it relates to a bad-boy protein, alpha-synuclein, not properly folding and running amok with your dopamine. (“Proteins folding” always sounded like laundry to me.)  But what causes the protein to mal-fold?  Bad genes?  Something in the environment? On…
  • Parkinson’s Movement: Clinical Trial Town Hall Session June 2016 Atlanta;  July 2016 Saint Joseph University, West Hartford Connecticut; September 2016, Grand Rapids What are Parkinson’s Clinical Trial Town Hall Sessions? The “Clinical Trials Town Hall” sessions aim to increase the visibility and build awareness of Parkinson’s research and clinical trials…